companies / adcytherix-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-16 json
| total_raised | 145,800,000145.8M | ○ |
|---|---|---|
| founded | 2024 | |
| hq | Marseille | |
| industry | unknown | |
| stage | series-a |
Adcytherix is a biopharmaceutical company developing novel antibody-drug conjugates for cancers with high unmet need. It targets cancer patients lacking effective options. Its pipeline is built around novel ADC payloads developed by a team carried over from Emergence Therapeutics.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-10-01 | series-a | 113,400,000113.4M | null | ○ |
Google Cloud CDN, Four, Sentry, core-js, WebsiteBuilder, Wix, Wix eCommerce, Google Cloud, React, lodash .
| fact | status | src |
|---|---|---|
| Series A, $113.4M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |